Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
about
Tracheal epithelium cell volume responses to hyperosmolar, isosmolar and hypoosmolar solutions: relation to epithelium-derived relaxing factor (EpDRF) effectsInhaled mannitol for cystic fibrosisCurrent and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implicationsNew and emerging targeted therapies for cystic fibrosisInhaled therapy in cystic fibrosis: agents, devices and regimensOptimising inhaled mannitol for cystic fibrosis in an adult populationFluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosisCystic fibrosis therapeutics: the road aheadUpdate in cystic fibrosis 2012.Testing two different doses of tiotropium Respimat® in cystic fibrosis: phase 2 randomized trial resultsState of progress in treating cystic fibrosis respiratory disease.A functional anatomic defect of the cystic fibrosis airway.Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.Children and young adults with CF in the USA have better lung function compared with the UK.Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.Ternary nanoparticles composed of cationic solid lipid nanoparticles, protamine, and DNA for gene delivery.Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumoniaProgress in cystic fibrosis and the CF Therapeutics Development NetworkHypertonic saline is effective in the prevention and treatment of mucus obstruction, but not airway inflammation, in mice with chronic obstructive lung diseaseInspiratory flows and volumes in subjects with cystic fibrosis using a new dry powder inhaler device.Mannitol dry powder for inhalation: in patients with cystic fibrosis.Effect of inhaled dry powder mannitol on mucus and its clearance.From pipeline to patient: new developments in cystic fibrosis therapeutics.Emerging drugs for cystic fibrosis.Efficacy and adverse effects of drugs used to treat adult cystic fibrosis.Challenges in the development of new therapies for bronchiectasis.New and Emerging Treatments for Cystic Fibrosis.Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.An update on pediatric bronchiectasis.New drug developments in the management of cystic fibrosis lung disease.Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial.Approaches to sample size calculation for clinical trials in rare diseases.
P2860
Q23914604-B634ED83-7201-4C3E-B110-8FFA48E5BEBAQ24186558-8647BB0C-DBB3-4803-8FD6-16340E4B80C4Q26747065-35E9BC44-31E0-4FE7-A360-4D88B75BB779Q26749278-92A2099A-14AA-4AB5-9E83-9AB929AA6E99Q26797450-A6F174AD-BC5B-467E-9D4B-B3B3B8BA03E1Q26797457-9C583E07-CFCD-47A9-A917-0FBF1C1F70F6Q27004711-B0A28BD0-4220-4661-B394-8EBC102B5712Q27022401-B2C76248-9DAE-4D39-B3A7-8869155D2038Q33738510-59DEA123-3F43-432B-B1B0-8DA45493DDC1Q34133948-CC87A94D-D950-4AE0-B8B5-A94E3D0B2866Q34375926-EE16A956-C43B-4351-8CFE-BEC280102E67Q34425996-A6E6304A-E4F7-426E-A3EB-92EB2001D414Q36144853-B5A16C4B-D1E5-4302-8E59-4246CB83C19DQ36818364-C1B52B8E-5E49-4921-BF12-6FD3DBF60E90Q36999197-B8CEC42D-8645-4886-A1AE-7193F18C8210Q37120644-70FD9F5E-EBC4-406D-A085-4FD1C606610AQ37147088-DF103192-D328-47D0-85CB-76A815731597Q37209004-40F80354-07EF-488B-9DE4-0702E3F39938Q37298002-95D8FC9C-07C9-4E66-8336-679EB8DC3C1CQ37601392-EE19BA42-33F0-47FB-A35B-61BFF1D42831Q38023470-4EA1E625-F394-4A20-B28B-78D773331A1CQ38077798-5AADA256-75DC-46DA-BEB3-C6F78C3B565DQ38078451-4AACE66A-5978-4E2B-9888-636A077EAB45Q38183476-75FB41D5-9DAA-4F51-BD31-21CDD616E9FEQ38325672-4C4E26A8-E3FF-4EC9-84B9-3A8C3424E226Q38387657-74A993AD-6589-4C0D-BD8E-91F43BFA5682Q38532426-24AA4E4B-AEDE-40B7-833C-D3720DE2E591Q38579967-A4640AB3-3035-40A8-A3D6-48A12B51755BQ38679480-E23A60BA-AC7F-48A6-8AD1-A66E615B5272Q38790382-5F6A6843-7BF3-49F0-820B-5DB9E2295F97Q41729344-98D4044E-D496-4FEF-95C3-F695B665E5FCQ43538692-BE453DFA-1332-4201-B503-5A4EBC3FD748Q45853347-E95295D8-D3ED-4148-89B6-CA03BA84A6F0Q48264067-E37DD080-9AFB-4366-9EFB-677AF956AB19
P2860
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Long-term inhaled dry powder m ...... nternational randomized study.
@en
Long-term inhaled dry powder m ...... nternational randomized study.
@nl
type
label
Long-term inhaled dry powder m ...... nternational randomized study.
@en
Long-term inhaled dry powder m ...... nternational randomized study.
@nl
prefLabel
Long-term inhaled dry powder m ...... nternational randomized study.
@en
Long-term inhaled dry powder m ...... nternational randomized study.
@nl
P2093
P2860
P1476
Long-term inhaled dry powder m ...... nternational randomized study.
@en
P2093
Allen Lapey
Brett Charlton
CF302 Investigators
David E Geller
Eric G Haarman
Gabriel Bellon
Helge U Hebestreit
Howard G Fox
I Manjula Schou
Jonathan B Zuckerman
P2860
P304
P356
10.1164/RCCM.201109-1666OC
P407
P577
2011-12-28T00:00:00Z